Predictors of malignancies and overall mortality in Japanese patients with biopsy-proven non-alcoholic fatty liver disease

Hepatology Research

Volumn 45, Issue 7, 2015, Pages 728-738

  Seko, Yuya ^a   Sumida, Yoshio ^a   Tanaka, Saiyu ^b   Taketani, Hiroyoshi ^b   Kanemasa, Kazuyuki ^b   Ishiba, Hiroshi ^a   Okajima, Akira ^a   Nishimura, Takeshi ^a   Yamaguchi, Kanji ^a   Moriguchi, Michihisa ^a   Mitsuyoshi, Hironori ^a   Yasui, Kohichiroh ^a   Minami, Masahito ^a   Itoh, Yoshito ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b Nara City Hospital   (Japan)

Author keywords

Hepatocellular carcinoma; Mortality; Non alcoholic fatty liver disease; Type IV collagen 7s

Indexed keywords

COLLAGEN TYPE 4;

ADOLESCENT; ADULT; AGED; ARTICLE; BILE DUCT CANCER; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CAUSE OF DEATH; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; JAPANESE (PEOPLE); LIVER BIOPSY; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; VERY ELDERLY;

EID: 84935055707     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12407     Document Type: Article

References (40)

1. Chalasani N, Younossi Z, Lavine JE etal. The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology 2012; 55: 2005-2023.
2. Ong JP, Pitts A, Younossi ZM. Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease. J Hepatol 2008; 49: 608-612.
3. Rafiq N, Bai C, Fang Y etal. Long-term follow-up of patients with nonalcoholic fatty liver. Clin Gastroenterol Hepatol 2009; 7: 234-238.
4. Angulo P, Bugianesi E, Bjornsson ES etal. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2013; 145: 782-789.
5. Musso G, Gambino R, Cassader M etal. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med 2011; 43: 617-649.
6. Wong VW, Wong GL, Tsang SW etal. High prevalence of colorectal neoplasm in patients with non-alcoholic steatohepatitis. Gut 2011; 60: 829-836.
7. Younossi ZM, Stepanova M, Rafiq N etal. Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality. Hepatology 2011; 53: 1874-1882.
8. Matteoni CA, Younossi ZM, Gramlich T etal. Nonalcoholic fatty liver diseases: a spectrum of clinical and pathological severity. Gastroenterology 1999; 116: 1413-1419.
9. Kleiner DE, Brunt EM, Van Natta M etal. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-1321.
10. Brunt EM, Janney CG, Di Bisceglie AM etal. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474.
11. Kawamura Y, Arase Y, Ikeda K etal. Large-scale long-term follow-up study of Japanese patients with non-alcoholic fatty liver disease for the onset of hepatocellular carcinoma. Am J Gastroenterol 2012; 107: 253-261.
12. Hashimoto E, Yatsuji S, Tobari M etal. Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. J Gastroenterol 2009; 44 (Suppl 19): 89-95.
13. White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 2012; 10: 1342-1359.
14. Katanoda K, Matsuda T, Matsuda A etal. An updated report of the trends in cancer incidence and mortality in Japan. Jpn J Clin Oncol 2013; 43: 492-507.
15. Arase Y, Kobayashi M, Suzuki F etal. Difference in malignancies of chronic liver disease due to non-alcoholic fatty liver disease or hepatitis C in Japanese elderly patients. Hepatol Res 2012; 42: 264-272.
16. Tilg H, Diehl AM. NAFLD and extrahepatic cancers: have a look at the colon. Gut 2011; 60: 745-746.
17. Armstrong MJ, Adams LA, Canbay A etal. Extra-hepatic complications of nonalcoholic fatty liver disease. Hepatology 2014; 59: 1174-1197.
18. Kodama K, Tokushige K, Hashimoto E etal. Hepatic and extrahepatic malignancies in cirrhosis caused by nonalcoholic steatohepatitis and alcoholic liver disease. Alcohol Clin Exp Res 2013; 37 (Suppl 1): E247-252.
19. Murawaki Y, Ikuta K, Koda M etal. Serum type III procollagen peptide, type IV collagen 7S domain, central triple helix of type IV collagen and tissue inhibitor of metalloproteinases in patients with chronic viral liver disease: relationship to liver histology. Hepatology 1994; 20: 780-787.
20. Sumida Y, Yoneda M, Hyogo H etal. A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease. J Gastroenterol 2011; 46: 257-268.
21. Yoneda M, Mawatari H, Fujita K etal. Type IV collagen 7s domain is an independent clinical marker of the severity of fibrosis in patients with nonalcoholic steatohepatitis before the cirrhoticstage. J Gastroenterol 2007; 42: 375-381.
22. Sorensen HT, Friis S, Olsen JH etal. Risk of liver and other types of cancer in patients with cirrhosis: a nationwide cohort study in Denmark. Hepatology 1998; 28: 921-925.
23. Goto K, Yokose T, Kodama T etal. Detection of early invasion on the basis of basement membrane destruction in small adenocarcinomas of the lung and its clinical implications. Mod Pathol 2001; 14: 1237-1245.
24. Burchardt ER, Hein R, Bosserhoff AK. Laminin, hyaluronan, tenascin-C and type IV collagen levels in sera from patients with malignant melanoma. Clin Exp Dermatol 2003; 28: 515-520.
25. Hirashima K, Iyama K, Baba Y etal. Differential expression of basement membrane type IV collagen α2 and α6 chains as a prognostic factor in patients with extrahepatic bile duct carcinoma. J Surg Oncol 2013; 107: 402-407.
26. Castro-Sanchez L, Soto-Guzman A, Navarro-Tito N etal. Native type IV collagen induces cell migration through a CD9 and DDR1-dependent pathway in MDA-MB-231 breast cancer cells. Eur J Cell Biol 2010; 89: 843-852.
27. Nyström H, Naredi P, Hafström L etal. Type IV collagen as a tumour marker for colorectal liver metastases. Eur J Surg Oncol 2011; 37: 611-617.
28. Ambiru S, Miyazaki M, Nakagawa K etal. Increased serum type IV collagen 7-S levels in patients with hepatic metastasis. Am J Gastroenterol 1995; 90: 783-787.
29. Kinoshita J, Fushida S, Harada S etal. Type IV collagen levels are elevated in the serum of patients with peritoneal dissemination of gastric cancer. Oncol Lett 2010; 1: 989-994.
30. Öhlund D, Franklin O, Lundberg E etal. Type IV collagen stimulates pancreatic cancer cell proliferation, migration, and inhibits apoptosis through an autocrine loop. BMC Cancer 2013; 13: 154.
31. Ohlund D, Lundin C, Ardnor B etal. Type IV collagen is a tumour stroma-derived biomarker for pancreas cancer. Br J Cancer 2009; 101: 91-97.
32. Targher G, Day CP, Bonora E. Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease. N Engl J Med 2010; 363: 1341-1350.
33. Choi SY, Kim D, Kim HJ etal. The relation between non-alcoholic fatty liver disease and the risk of coronary heart disease in Koreans. Am J Gastroenterol 2009; 104: 1953-1960.
34. Kim D, Choi SY, Park EH etal. Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatology 2012; 56: 605-613.
35. Donghee K, Kim WR, Kim HJ etal. Association between noninvasive fibrosis markers and mortality among adults with nonalcoholic fatty liver disease in the United States. Hepatology 2013; 57: 1357-1365.
36. Stepanova M, Rafiq N, Makhlouf H etal. Predictors of all-cause mortality and liver-related mortality in patients with non-alcoholic fatty liver disease (NAFLD). Dig Dis Sci 2013; 58: 3017-3023.
37. Bhala N, Angulo P, van der Poorten D etal. The natural history of nonalcoholic fatty liver disease with advanced fibrosis or cirrhosis: an international collaborative study. Hepatology 2011; 54: 1208-1216.
38. Leeming DJ, Karsdal MA, Rasmussen LM etal. Association of systemic collagen type IV formation with survival among patients undergoing hemodialysis. PLoS One 2013; 8 (8): e71050.
39. Kawamura M, Yamasawa F, Ishizaka A etal. Serum concentration of 7S collagen and prognosis in patients with the adult respiratory distress syndrome. Thorax 1994; 49: 144-146.
40. Sato Y, Kataoka K, Matsumori A etal. Measuring serum aminoterminal type III procollagen peptide, 7S domain of type IV collagen, and cardiac troponin T in patients with idiopathic dilated cardiomyopathy and secondary cardiomyopathy. Heart 1997; 78: 505-508.